UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  June 15, 2010

Keryx Biopharmaceuticals, Inc.
 (Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)
  
000-30929
(Commission File Number)
  
13-4087132
(IRS Employer Identification
No.)

750 Lexington Avenue
New York, New York 10022
 (Address of Principal Executive Offices)

(212) 531-5965
 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 
¨
Written communications pursuant to Rule 425 under the Securities Act.
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
 
¨
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

The 2010 annual meeting of stockholders of Keryx Biopharmaceuticals, Inc. (“Keryx”) was held on June 15, 2010.  The following matters were voted on by the stockholders: the election of directors, and the ratification of the appointment of UHY LLP as Keryx’s independent registered public accounting firm for the year ending December 31, 2010. At the meeting, Ron Bentsur, Kevin J. Cameron, Wyche Fowler, Jr., Jack Kaye and Michael P. Tarnok were re-elected to the Board.

The vote with respect to each nominee is set forth below:

Nominee
  
Total Votes For
  
Total Votes
Withheld
  
Broker Non-Votes
Ron Bentsur
  
8,246,201
  
1,236,103
  
30,838,067
Kevin J. Cameron
  
8,556,615
  
925,689
  
30,838,067
Wyche Fowler, Jr.
  
9,179,607
  
302,697
  
30,838,067
Jack Kaye
  
9,183,807
  
298,497
  
30,838,067
Michael P. Tarnok
  
9,185,607
  
296,697
  
30,838,067

The vote with respect to the ratification of the appointment of UHY LLP as Keryx’s independent registered public accounting firm for the year ending December 31, 2010, is set forth below.

Total Votes For
  
Total Votes Against
  
Abstention
40,048,685
  
141,136
  
130,550

 
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Keryx Biopharmaceuticals, Inc.
 
(Registrant)
     
Date:  August 5, 2010
    
     
 
By:
/s/ James F. Oliviero
   
James F. Oliviero
   
Chief Financial Officer